Guadagni F, Roselli M, Cosimelli M, Spila A, Cavaliere F, Tedesco M, Arcuri R, Abbolito M R, Casale V, Pericoli M N, Vecchione A, Casciani C U, Greiner J W, Schlom J
Laboratory of Clinical Pathology, Regina Elena Cancer Institute, Rome, Italy.
Cancer Res. 1996 Nov 15;56(22):5293-8.
Colorectal tissue biopsies were obtained from 110 patients diagnosed with primary colorectal carcinoma (tumor and normal colonic mucosa samples), 20 patients diagnosed with benign colorectal disease, and 31 healthy donors. The level of expression of tumor-associated glycoprotein 72 (TAG-72) was quantitatively measured in each sample using a double-determinant RIA with monoclonal antibodies B72.3 and CC49 and detecting the sialyl-Tn epitope; this assay was termed CA 72-4. Statistical analysis revealed a significant (approximately 10-fold) increase of TAG-72 expression in the colon tumor biopsies when compared with the expression in normal colonic mucosa from the same patients. A regression analysis revealed a significant correlation (r = 0.459; P < 0.001) between TAG-72 levels measured in biopsies from the tumor lesions and those found in the corresponding normal colonic mucosa. Furthermore, regression analysis showed a significant positive correlation between TAG-72 levels in the tumors and sera of the same patients (r = 0.491; P < 0.001). TAG-72 levels in normal colonic mucosa from healthy donors and patients diagnosed with colorectal cancer were compared. TAG-72 expression was 5-fold higher in the normal mucosa from the colorectal carcinoma patients. No relationship between TAG-72 tumor tissue content and stage of disease was found. Moreover, the correlation between TAG-72 distribution and degree of tumor differentiation observed (P < 0.05) was not any more evident when mucinous carcinomas were excluded. Finally, the results provide further evidence that TAG-72 may be considered an important early marker for colorectal cancer and/or other dysplastic colonic diseases. The statistical correlation between TAG-72 levels in tumors and circulating TAG-72 indicates that patients with elevated levels of serum TAG-72, as measured by the CA 72-4 assay, would be most suited for diagnostic and/or therapeutic intervention with the anti-TAG-72 monoclonal antibodies B72.3 or CC49 or vaccine trials using the sialyl-Tn epitope.
从110例诊断为原发性结直肠癌的患者（肿瘤及正常结肠黏膜样本）、20例诊断为良性结直肠疾病的患者以及31名健康供体获取了结直肠组织活检样本。使用针对单克隆抗体B72.3和CC49的双决定簇放射免疫分析并检测唾液酸化-Tn表位，对每个样本中肿瘤相关糖蛋白72（TAG-72）的表达水平进行定量测定；该检测方法称为CA 72-4。统计分析显示，与同一患者正常结肠黏膜中的表达相比，结肠肿瘤活检样本中TAG-72的表达显著增加（约10倍）。回归分析显示，肿瘤病变活检样本中测得的TAG-72水平与相应正常结肠黏膜中测得的TAG-72水平之间存在显著相关性（r = 0.459；P < 0.001）。此外，回归分析表明，同一患者肿瘤中的TAG-72水平与血清中的TAG-72水平之间存在显著正相关（r = 0.491；P < 0.001）。比较了健康供体和诊断为结直肠癌的患者正常结肠黏膜中的TAG-72水平。结直肠癌患者正常黏膜中的TAG-72表达高5倍。未发现TAG-72肿瘤组织含量与疾病分期之间存在关联。此外，排除黏液癌后，观察到的TAG-72分布与肿瘤分化程度之间的相关性（P < 0.05）不再明显。最后，结果提供了进一步的证据表明，TAG-72可被视为结直肠癌和/或其他发育异常的结肠疾病的重要早期标志物。肿瘤中的TAG-72水平与循环中的TAG-72之间的统计相关性表明，通过CA 72-4检测测得血清TAG-72水平升高的患者最适合使用抗TAG-72单克隆抗体B72.3或CC49进行诊断和/或治疗干预，或使用唾液酸化-Tn表位进行疫苗试验。
